ANXA5 and colitis: ANXA5 is a well‐recognized PS‐binding protein, and as such, has been widely used in apoptosis assays in vitro.[31, 32] By tail vein injection of ANXA5‐RFP protein, we found that colonic PS exposure in healthy mice was 4.15 times higher than that in the duodenum, whereas the level of colonic PS exposure was increased to 92.05 times higher than that in the duodenum under pathologic conditions of enterocolitis, suggesting that PS is more highly exposed at the site of colonic pathology under pathologic conditions and is a potential therapeutic target for colitis.